RUNX2 and osteosarcoma: The nitric oxide (NO) treatment of the MG-63 osteosarcoma cell line was shown to enhance RUNX2-mediated BCL2 expression, which improves cell viability under oxidative stress [49], in contrast to results that suggested that RUNX2 upregulates BAX expression in the SAOS-2 cell line [8].